Web Analytics Made Easy - StatCounter
Category

Neurologic Manifestations

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.

By | Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Serena Silvestro, Santa Mammana, Eugenio Cavalli, Placido Bramanti, Emanuela Mazzon
Molecules, April 2019

Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, n…

Read More

Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.

By | Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Giulia S. Porcaria, Cary Fub, Emily D. Doll, Emma G. Carter, Robert P. Carson
Epilepsy & Behavior, March 2018

Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures. Cannabidiol (CBD), one of many constituents of the Cannabis sativa or marijuana plant, has rece…

Read More

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

By | Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Orrin Devinsky, Eric Marsh, Daniel Friedman, Elizabeth Thiele, Linda Laux, et al
The Lancet Neurology, March 2016

BACKGROUND: Almost a third of patients with epilepsy have a treatment-resistant form, which is associated with severe morbidity and increased mortality. Cannabis-based treatments for epilepsy have generated much interest, but scientific data are scarce. We aimed to establish w…

Read More

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

By | Behavioral Health, Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez‐Ruiz, et al
Epilepsia, June 2014

To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant…

Read More

Pain measurements and side effect profile of the novel cannabinoid ajulemic acid.

By | Nervous System Diseases, Neurologic Manifestations, Pain

Authors: Kahlid Salim, Udo Schneider, Sumner Burstein, Ludwig Hoy, Matthias Karst
Neuropharmacology, June 2005

Preclinical findings on ajulemic acid (AJA) showed analgesic and anti-allodynic effects without psychoactive properties making it an appealing substance for the treatment of pain. A recently published randomized double-blind crossover clinical trial described the pain-reducing…

Read More

The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.

By | Brain Disorders, Epilepsy, Nervous System Diseases, Neurologic Manifestations

Authors: Melisa J. Wallace, Robert E. Blair, Katherine W. Falenski, Billy R. Martin, Robert J. DeLorenzo
Journal of Pharmacology and Experimental Therapeutics, October 2003

Several lines of evidence suggest that cannabinoid compounds are anticonvulsant. However, the anticonvulsant potential of cannabinoids and, moreover, the role of the endogenous cannabinoid system in regulating seizure activity has not been tested in an in vivo model of epileps…

Read More